Exelixis: Phase 3 Combination Study for Melanoma Didn't Meet Primary Endpoint
June 20 2019 - 7:37PM
Dow Jones News
By Josh Beckerman
Exelixis Inc. (EXEL) said a Phase 3 drug trial evaluating the
combination of cobimetinib and atezolizumab to treat melanoma
didn't meet its primary endpoint of progression-free survival.
Exelixis discovered cobimetinib, which was approved in the U.S.
in 2015 and is co-promoted by Roche Holding AG's (ROG.EB) Genentech
unit. Atezolizumab was developed by Genentech.
The safety profile observed in the IMspire170 trial was
consistent with the known safety profiles of the individual drugs,
Exelixis said.
Genentech, the sponsor of the trial, plans to present results at
an upcoming medical meeting.
Exelixis shares fell 6.5% to $19.77 after hours.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
June 20, 2019 19:22 ET (23:22 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
